RAC shareholders are the closest they have ever been to commercialisation.
The only thing that really matters is how efficiently RAC can build value for Bisantrene from the date the peripheral IV patent is accepted to buyout negotiations.
The Board and Management are now completely aligned with maximising value for shareholders.
Dosing a patient this side of Christmas means nothing in comparison to excellent execution of a well-planned CPACS trial design or proving Bisantrene synergises effectively with Tyrosine Kinase inhibitors or improves acquired resistance rates for Immune Checkpoint Blockade.
Add to My Watchlist
What is My Watchlist?
